LAVA-051

LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024 In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking toQ2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.(NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2023. “In 2023, we advanced our portfolio of proprietary Gammabody® programs. LAVA-1207 has enrolled dose level 9 in our Phase 1/2a trial of patients with metastatic castration-resistant prostate cancer (mCRPC). We will soon be enrolling the patients in our pembrolizumab combination arm. We continue to be encouraged by the favorable safety pro preliminary signs of anti-tumor activity. We plan to provide new data for LAVA-1207 at an upcoming medical conference in the second half of 2024,” said Stephen Hurly, President and Chief Executive Officer of LAVA. “We are also very excited by Pfizer’s clinical progress. They have been a great partner and we look forward to continuing to support them. We plan to submit an IND for LAVA-1266, our investigational asset designed to target CD123 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), in Q2 2024,” continued Mr. Hurly. “These advances represent important steps for our proprietary Gammabody® T-cell engagers as we evaluate their potential to treat cancer. We believe that 2024 will be a significant year and we look forward to sharing our ongoing progress with investors and stakeholders.” LAVA 1207 – In Phase 1/2a -- Next update expected H2 2024 targeting a medical conference Designed to mediate potent killing of prostate-specific membrane antigen (PSMA)-positive prostate cancer cells The first-in-human Phase 1/2a clinical trial is enrolling patients in monotherapy and combination arms Completed enrollment in dose level 9 monotherapy arm. Expect to begin enrolling in the dose escalation and dose expansion arm, in combination with KEYTRUDA® (pembrolizumab) in the coming months Evaluating low dose Interleukin-2 (“IL-2”) in the Phase 1/2a study in order to increase the number of Vγ9Vδ2 T cells for engagement by LAVA-1207 With the goal of maintaining low rates of cytokine release syndrome (CRS) and to minimize the risk of CRS events >grade 2, we have introduced premedication and step-dosing to the protocol. Three dose limiting toxicities (DLTs) were observed in patients receiving IL-2 in addition to LAVA-1207, in a cohort with multiple doses of IL-2 per cycle. Since we amended the DLT criteria and initiated step dosing, we have not observed any CRS or DLTs in patients dosed with IL-2 to date. Additional biomarker studies are underway to understand the relationship between δ2 T cells and tumor response, and to investigate other factors that may impact patient selection and show early evidence of anti-tumor activity. EGFRd2 (PF-08046052/formerly LAVA-1223) – In Phase 1 Designed to trigger the potent and preferential killing of EGFR-positive tumor cells in solid tumors such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC) Potential first-in-class agent Dose escalation trial is underway to evaluate the safety and tolerability of EGFRd2 (PF-08046052) as a monotherapy in advanced EGFR-expressing solid tumors In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone LAVA-1266 – IND Submission Expected in Q2 2024 Designed to target CD123 for the treatment of hematological malignancies, including AML and MDS Currently engaged in IND enabling activities Planning for IND submission in Q2 2024 Fourth Quarter and Year-End 2023 Financial Results As of December 31, 2023, LAVA had cash, cash equivalents and investments totaling $95.6 million compared to cash, cash equivalents and investments of $132.9 million as of December 31, 2022. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2026. Revenue from contracts with customers was $0.4 million and $2.6 million for the quarters ended December 31, 2023 and 2022, respectively, and $6.8 million and $19.4 million for the years ended December 31, 2023 and 2022, respectively. In connection with the license agreement with Pfizer (formerly Seagen), we recognized $0.3 million in revenue for the three months ended December 31, 2023, related to reimbursement for research activities and initial supply-related stability studies, and $2.6 million for the three months ended December 31, 2022. The decrease of revenue from contracts with customers for the year ended December 31, 2023 compared to 2022 was primarily due to a $15.2 million nonrefundable upfront payment received in 2022 in connection with the Pfizer agreement. Cost of sales of goods and providing services was $0.2 million and zero for the quarters ended December 31, 2023 and 2022, respectively, and $3.5 million and zero for the years ended December 31, 2023 and 2022, respectively. The cost in 2023 was due to the initial drug supply delivery to Pfizer and related stability studies. Research and development expenses were $3.4 million and $10.5 million for the quarters ended December 31, 2023 and 2022, respectively, and $33.8 million and $40.1 million for the years ended December 31, 2023 and 2022, respectively. The decrease for both periods was primarily due to reduced manufacturing scale-up costs, negotiated reduction in contract manufacturing invoices, and reduced clinical trial activities due to the discontinuation of the activities for LAVA-051, announced in June 2023. General and administrative expenses were $2.3 million and $3.6 million for the quarters ended December 31, 2023 and 2022, respectively, and $12.7 million and $14.1 million for the years ended December 31, 2023 and 2022, respectively. The decrease for both periods was primarily due to lower personnel-related expenses due to a reduction in general and administrative headcount in 2023. Net loss was $6.5 million and $14.9 million for the quarters ended December 31, 2023 and 2022, respectively, or $0.24 and $0.57 net loss per share for the quarters ended December 31, 2023 and 2022, respectively. Net losses were $42.0 million and $31.9 million for the years ended December 31, 2023 and 2022, respectively, or $1.57 and $1.23 net loss per share for the years ended December 31, 2023 and 2022, respectively. LAVA Therapeutics N.V. Consolidated Interim Statements of Loss and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 Revenue: Revenue from contracts with customers $ 353 $ 2,640 $ 6,769 $ 19,391 Cost of sales of goods — — (2,546 ) — Cost of providing services (154 ) — (936 ) — Gross profit 199 2,640 3,287 19,391 Operating expenses: Research and development (3,360 ) (10,540 ) (33,814 ) (40,105 ) General and administrative (2,281 ) (3,579 ) (12,726 ) (14,124 ) Total operating expenses (5,641 ) (14,119 ) (46,540 ) (54,229 ) Operating loss (5,442 ) (11,479 ) (43,253 ) (34,838 ) Interest income (expense), net 846 471 2,970 257 Foreign currency exchange (loss) gain, net (1,841 ) (3,840 ) (1,412 ) 2,923 Total non-operating income (995 ) (3,369 ) 1,558 3,180 Loss before income tax (6,437 ) (14,848 ) (41,695 ) (31,658 ) Income tax expense (61 ) (67 ) (279 ) (249 ) Loss for the year $ (6,498 ) $ (14,915 ) $ (41,974 ) $ (31,907 ) Items that may be reclassified to profit or loss Foreign currency translation adjustment 2,155 7,471 2,073 (6,749 ) Total comprehensive loss $ (4,343 ) $ (7,444 ) $ (39,901 ) $ (38,656 ) Loss per share: Loss per share, basic and diluted $ (0.24 ) $ (0.57 ) $ (1.57 ) $ (1.23 ) Weighted-average common shares outstanding, basic and diluted 26,769,937 26,289,087 26,732,556 25,924,005 LAVA Therapeutics N.V. Consolidated Statements of Financial Position (in thousands) (unaudited) As of December 31, 2023 2022 Assets Non-current assets: Property and equipment, net $ 1,602 $ 1,432 Right-of-use assets 892 651 Other non-current assets and security deposits 319 809 Total non-current assets 2,813 2,892 Current assets: Receivables and other 1,459 3,254 Prepaid expenses and other current assets 1,627 4,411 VAT receivable 240 — Investments 51,340 32,535 Cash and cash equivalents 44,231 100,333 Total current assets 98,897 140,533 Total assets $ 101,710 $ 143,425 Equity and Liabilities Equity: Share capital $ 3,715 $ 3,715 Equity-settled employee benefits reserve 12,005 8,942 Foreign currency translation reserve (10,899 ) (12,972 ) Additional paid-in capital 194,424 194,424 Accumulated deficit (148,067 ) (108,069 ) Total equity 51,178 86,040 Non-current liabilities: Deferred revenue 35,000 35,000 Lease liabilities 591 431 Total non-current liabilities 35,591 35,431 Current liabilities: Trade payables and other 4,446 3,965 VAT payable — 45 Borrowings 5,282 4,640 Lease liabilities 440 379 License liabilities — 4,732 Accrued expenses and other current liabilities 4,773 8,193 Total current liabilities 14,941 21,954 Total liabilities 50,532 57,385 Total equity and liabilities $ 101,710 $ 143,425 About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation study (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a study evaluating monotherapy and combination treatment with interleukin-2 (IL-2). The Company is also planning to expand the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab), through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit , and follow us on LinkedIn, X, and YouTube. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA’s Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including with respect to the Company’s anticipated growth and clinical development plans including the timing and results of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential,” “suggests” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements relating to the therapeutic potential, development and potential uses of LAVA’s product candidates, the timing of initiation of clinical trials, including the expansion phase of the Phase 1/2a trial to evaluate LAVA-1207 in combination with KEYTRUDA®, the potential of premedication and step-dosing to minimize the risk of CRS in our Phase 1/2a clinical trial for LAVA-1207, use of biomarkers and assays for patient selection, the relationship between γδ2 T cells and antitumor activity, the timing of regulatory submissions, availability of information regarding clinical development plans, progress and data from clinical trials, the potential uses of LAVA’s product candidates to treat various tumor targets, including AML, MDS, mCRPC, CRC, NSCLC, and HNSCC, and improve patient outcomes, LAVA’s cash runway and the sufficiency of resources to pursue development activities. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, the Company’s ability to leverage its initial programs to develop additional product candidates using our Gammabody® platform, and the failure of LAVA’s collaborators to support or advance collaborations or LAVA’s product candidates, the timing and results of LAVA’s research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur, in clinical trials, the risk that results obtained in clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, the Company’s ability to obtain regulatory approval for an commercialize its product candidates, the risk that setbacks in development could occur in clinical trials even after promising results in earlier trials or preclinical studies, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on the Company’s business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, the Russian invasion of Ukraine and the Israel- Hamas war, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures. These and other risks are described in greater detail under the caption “Risk Factors” and included in LAVA’s filings with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. CONTACTS Investor Relations ir@lavatherapeutics.com LifeSci Advisors (IR/Media) Joyce Allaire Jallaire@lifesciadvisors.com

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody® platform as a monotherapy in advanced EGFR expressing solid tumorsSelection of undisclosed lead candidate by Janssen Biotech triggered an onboarding milestone paymentLAVA plans to submit IND for Gammabody targeting CD123 in 1H 2024 (LAVA-1266)Strong balance sheet with cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, today announced recent corporate highlights and financial results for the quarter ended September 30, 2023. “We continue to advance our lead program, LAVA-1207, in patients with mCRPC in our Phase 1/2a escalation study,” said Steve Hurly, president and chief executive officer of LAVA. “Our Gammabody® platform continues to receive the support of investigators and patients, and enrollment remains on track. We are also pleased with the progress of our partnered programs, particularly the initiation of the Phase 1 study of SGN-EGFRd2 (LAVA-1223) in advanced solid tumors which provides additional validation of our platform. With an expected cash runway into 2026, LAVA remains well-positioned to bring meaningful benefits to patients in areas of high unmet need and to deliver shareholder value.” LAVA-1207 Gammabody® designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells in patients with metastatic castration-resistant prostate cancer (mCRPC). The safety, tolerability, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of LAVA-1207 in patients with mCRPC are being evaluated in an ongoing dose escalation phase 1/2a, first-in-human study. Trial enrollment is progressing across 10 clinical trial sites in Europe and the United States.The Company expects to report additional data for the dose escalation phase of the trial in the third quarter of 2024, which if positive, we expect these results to allow us to rapidly design and enter into a dose expansion study to support a potential pivotal future trial. Partnered Programs Seagen- SGN-EGFRd2 (LAVA-1223) During the third quarter, Seagen began recruitment in a Phase 1 study evaluating the safety and tolerability of SGN-EGFRd2 (LAVA-1223) as a monotherapy administered intravenously in advanced solid tumors. The study design has three parts: Parts A and B of the study will identify dosage for SGN-EGFRd2 and Part C will use the findings in Parts A and B for a dose to determine safety and efficacy of SGN-EGFRd2. Eligible patients for Part A include patients with colorectal cancer, non-small cell lung cancer or head and neck squamous cancer that is relapsed, refractory, or be intolerant to standard of care therapies. For more information, please refer to clinicaltrials.gov (NCT05983133). Janssen Biotech - Undisclosed Candidate Earlier this year, Janssen selected a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards a phase 1 clinical trial. A milestone payment was received in July 2023. Third Quarter 2023 Financial Results The financial information provided below reflects changes made to previously issued consolidated financial statements to revise immaterial prior-period misstatements. Further information regarding the revision is included in LAVA’s consolidated financial statements, "Note 12 — Revision of Immaterial Misstatements," included in Exhibit 99.1 to the report on Form 6-K to be filed with the SEC on the date hereof. As of September 30, 2023, LAVA had cash, cash equivalents and investments totaling $104.6 million compared to cash, cash equivalents and investments of $132.9 million as of December 31, 2022. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2026.Revenue from contracts with customers was less than $0.1 million and $15.3 million for the quarters ended September 30, 2023 and 2022, respectively, and $3.1 million and $16.8 million for the nine months ended September 30, 2023 and 2022, respectively. In connection with the license agreement with Seagen, we recognized less than $0.1 million in revenue for the three months ended September 30, 2023, related to reimbursement for research activities and initial supply related stability studies. Revenue from contracts with customers was $15.3 million for the three months ended September 30, 2022, related to the Seagen Agreement. Of that amount, $15.2 million related to the nonrefundable upfront payment and $0.1 million related to reimbursement for research activities.Cost of providing services and sales of goods was less than $0.1 million and zero for the quarters ended September 30, 2023 and 2022, respectively, and $3.3 million and zero for the nine months ended September 30, 2023 and 2022, respectively. The increase in cost was due to the cost of the initial supply delivery to Seagen and related stability studies.Research and development expenses were $7.9 million and $13.7 million for the quarters ended September 30, 2023 and 2022, respectively, and $30.5 million and $29.6 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease was primarily due to reduced manufacturing scale-up costs and clinical trial activities due to the discontinuation of the activities for LAVA-051, announced in June 2023.General and administrative expenses were $2.9 million and $3.1 million for the quarters ended September 30, 2023 and 2022, respectively, and $10.4 million and $10.5 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease for both periods was primarily due to lower personnel-related expenses due to a reduction in general and administrative headcount.Net loss was $8.8 million and net profit was $0.9 million for the quarters ended September 30, 2023 and 2022, respectively, or $0.34 net loss and $0.04 net profit per share for the quarters ended September 30, 2023 and 2022, respectively. Net losses were $35.5 million and $17 million for the nine months ended September 30, 2023 and 2022, respectively, or $1.35 and $0.66 net loss per share for the nine months ended September 30, 2023 and 2022, respectively. LAVA Therapeutics N.V.Condensed Consolidated Interim Statements of Profit and Lossand Comprehensive Profit and Loss(in thousands, except share and per share amounts) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Revenue from contracts with customers $53 $15,261 $6,416 $16,751 Cost of sales of goods — — (2,546) — Cost of providing services (10) — (782) — Gross profit 43 15,261 3,088 16,751 Operating expenses: Research and development (7,912) (13,697) (30,454) (29,565)General and administrative (2,858) (3,135) (10,445) (10,545)Total operating expenses (10,770) (16,832) (40,899) (40,110) Operating loss (10,727) (1,571) (37,811) (23,359)Interest income (expense), net 809 39 2,124 (214)Foreign currency exchange gain, net 1,132 2,515 429 6,763 Total non-operating income 1,941 2,554 2,553 6,549 (Loss) Profit before income tax (8,786) 983 (35,258) (16,810)Income tax expense (50) (47) (218) (182)(Loss) Profit for the period $ (8,836) $ 936 $ (35,476) $ (16,992)Items that may be reclassified to profit or loss Foreign currency translation adjustment (1,385) (5,359) (82) (14,220)Total comprehensive loss $ (10,221) $ (4,423) $ (35,558) $ (31,212) (Loss) Profit per share: (Loss) Profit per share, basic $(0.34) $0.04 $(1.35) $(0.66)Weighted-average common shares outstanding, basic 26,289,087 25,845,802 26,289,087 25,800,973 (Loss) Profit per share, diluted $(0.34) $0.04 $(1.35) $(0.66)Weighted-average common shares outstanding, diluted 26,289,087 26,446,259 26,289,087 25,800,973 LAVA Therapeutics N.V.Condensed Consolidated Statements of Financial Position(in thousands) (unaudited) September 30, December 31, 2023 2022 Assets Non-current assets: Property and equipment, net $1,715 $1,432 Right-of-use assets 1,062 651 Other non-current assets and security deposits 326 809 Total non-current assets 3,103 2,892 Current assets: Receivables and other 1,077 3,254 Prepaid expenses and other current assets 1,906 4,411 VAT receivable 307 — Investments 41,964 32,535 Cash and cash equivalents 62,663 100,333 Total current assets 107,917 140,533 Total assets $ 111,020 $ 143,425 Equity and Liabilities Equity: Share capital $3,715 $3,715 Equity-settled employee benefits reserve 11,421 8,942 Foreign currency translation reserve (13,054) (12,972)Additional paid-in capital 194,424 194,424 Accumulated deficit (141,910) (108,069)Total equity 54,596 86,040 Non-current liabilities: Deferred revenue 35,000 35,000 Lease liabilities 671 431 Total non-current liabilities 35,671 35,431 Current liabilities: Trade payables and other 9,384 3,965 VAT payable — 45 Borrowings 4,944 4,640 Lease liabilities 580 379 License liabilities — 4,732 Accrued expenses and other current liabilities 5,845 8,193 Total current liabilities 20,753 21,954 Total liabilities 56,424 57,385 Total equity and liabilities $ 111,020 $ 143,425 About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States (NCT05369000). The Company’s collaborations include a license agreement with Seagen for the clinical development of SGN-EGFRd2 (LAVA-1223). For more information, please visit and follow us on LinkedIn, X (formerly known as Twitter), and YouTube. LAVA’s Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including with respect to the Company’s anticipated growth and clinical development plans including the timing and results of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential,” “suggests” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements about the expected safety profile of LAVA’s product candidates, preclinical data, clinical development and the scope of clinical trials, including the availability of data therefrom, expectations regarding enrollment in clinical trials, the potential use of the Company’s product candidates to treat various tumor targets, and the Company’s expected cash runway. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of LAVA’s research and development programs and preclinical and clinical trials, the risk that results obtained in clinical trials to date may not be indicative of results obtained in ongoing or future trials, the Company’s ability to obtain regulatory approval for and commercialize its product candidates, including combinations of LAVA product candidates to increase the number of Vγ9Vδ2-T cells, the Company’s ability to leverage its initial programs to develop additional product candidates using our Gammabody® platform, including the expectation of submitting an IND for LAVA-1266 in 1H2024 and the failure of LAVA’s collaborators to support or advance collaborations or LAVA’s product candidates. There may be adverse effects on the Company’s business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, rising interest rates, recent and potential future pandemics and other health crises, hostilities between Russia and Ukraine or in the Middle East, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures. These and other risks are described in greater detail under the caption “Risk Factors” and included in LAVA’s filings with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. CONTACTSInvestor Relationsir@lavatherapeutics.com Argot Partners (IR/Media)212-600-1902lava@argotpartners.com